Stock fact sheet · data as of
Elutia Inc (ELUT): fair value, margin of safety and Wheel Score
Healthcare · Biotechnology · United States · Value
Is ELUT undervalued?
At 0.7888 (close of 16 Oct 2026), ELUT trades 97% below the GLS average fair value of 24.46. That average comes from 6 models run on the latest filings, and 5 of them land above the current price. Margins of safety over 30% are the exception rather than the rule across the ~7,400 stocks we value each night, so the number earns Elutia Inc the full Value points in the Wheel Score - and a closer look at what the market is pricing in.
The 6 models disagree widely: DCF gives 0.0941 while Graham Growth gives 67.93. A spread that wide means the average is sensitive to which methods you trust; the model table below shows where each one lands, and the Quote page lets you switch any of them off.
The nightly engine files ELUT under Value: positive earnings at a P/E of 18 or less.
Nine valuation models for ELUT
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | 0.0941 | -88% | Present value of the projected free cash flows, discounted at the cost of capital |
| Graham Number | 3.11 | +294% | The most a defensive investor pays for the earnings and book value per share |
| Graham Growth | 67.93 | +8512% | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields |
| Lynch | 29.69 | +3664% | EPS × the earnings growth rate (PEG of 1), growth capped at 25% |
| GLS Growth | 32.77 | +4054% | EPS compounded ten years at the blended growth rate, discounted back at 15% a year |
| 10 Cap | - | - | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | 13.20 | +1573% | Earnings power value: current EPS capitalised at 9% with no growth |
| Zombie (liquidation) | 0.4773 | -39% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 8.88 | +1026% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Financial health is average - ELUT passes 5 of the nine Piotroski tests, which falls one point short of the Sunday Scan's "6 or more" rule. The Financials tab on the Quote page shows which tests fail. The GLS Moat score is low at 2.5 out of 10, which says the ten-year record of revenue, earnings, margins and returns on capital has been inconsistent - growth and shocks rather than steady compounding.
Returns on capital are high - ROIC 137.4%, ROE 192.9%, ROA 85.6% - with debt at 0.40 times equity and negative free cash flow.
Elutia Inc pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Women's Health 53%, Cardiovascular 47% (quarter Q2 FY2026).
Institutional ownership scores 5/10, insider activity 10/10 and Congressional trading 5/10 on the GLS smart-money scales; the last recorded insider buy was on 10 Sep 2026.
| Piotroski F-score | 5 / 9 | ROIC | 137.4% |
|---|---|---|---|
| GLS Moat | 2.5 / 10 | ROE | 192.9% |
| Debt / equity | 0.40 | ROA | 85.6% |
| Free-cash-flow yield | -130.2% | Payout ratio | 0% |
| Institutions | 5 / 10 | Insiders · Congress | 10 · 5 / 10 |
Wheel Score 39: No options
ELUT has no listed options in the nightly snapshot, so there is nothing to sell and the stock cannot be wheeled however good the business; the Wheel Score is capped at 39 and shown as "No options" (39 here). The valuation and quality numbers still apply to owning the shares outright.
Volume runs at 124k shares a day on a market cap of $35M, with a beta of 0.84; the Stability part of the Wheel Score gives that 7 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 25 / 25 | 97% margin of safety | |
| Health | 11 / 20 | Piotroski 5/9 | |
| Moat | 4 / 15 | moat 2.5/10 | |
| Premium | 0 / 20 | no option data | |
| Stability | 7 / 20 | 124k shares/day, $35M cap, beta 0.84 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
The next earnings report is due on 12 Nov 2026, 27 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Biotechnology
The 12 companies below are the closest to Elutia Inc by market cap within the Biotechnology industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| NNVC NanoViricides, Inc. | 1.37 | 1,583,177.91 | +100% | 45Weak | $35M |
| IXHL Incannex Healthcare Limited | 2.88 | 4.02 | +28% | 37Weak | $34M |
| CRVO CervoMed Inc. | 2.25 | 0.8036 | -180% | 15No options | $34M |
| ELTX Elicio Therapeutics, Inc. | 1.78 | 0.2252 | -691% | 15Weak | $34M |
| IRLA IRulya Therapeutics Inc. | 33.23 | - | - | 25Weak | $34M |
| ALGS Aligos Therapeutics, Inc. | 5.39 | 0.1520 | -3446% | 12No options | $34M |
| VERU Veru Inc. | 2.13 | 0.6643 | -221% | 18Weak | $36M |
| LITS Lite Strategy, Inc. | 1.20 | 0.1580 | -656% | 18Weak | $36M |
| ATNM Actinium Pharmaceuticals, Inc. | 1.06 | 3.20 | +67% | 49Weak | $33M |
| FLNA Filana Therapeutics, Inc. | 0.7608 | 1.85 | +59% | 41Weak | $37M |
| EXOZ eXoZymes, Inc. | 4.00 | 0.1426 | -2706% | 5No options | $37M |
| BCTX BriaCell Therapeutics Corp. | 3.77 | 4.14 | +9% | 29No options | $33M |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about ELUT
Is ELUT undervalued right now?
By the GLS models, yes: at 0.7888 the stock is 97% below the average fair value of 24.46 (data as of 16 Oct 2026). Whether the discount is deserved is the question to research next.
What is the Wheel Score of ELUT and what does it mean?
ELUT has no listed options in our nightly snapshot, so it cannot be wheeled; its Wheel Score is capped at 39 and shown as "No options".
What is the GLS fair value for ELUT?
24.46 per share as of 16 Oct 2026 - the simple average of the 6 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Elutia Inc report earnings next?
The next earnings report is due on 12 Nov 2026, 27 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does ELUT have listed options, and how liquid are they?
No. The nightly options snapshot found no listed contracts on ELUT, so the wheel strategy cannot be run on it and the Wheel Score is capped at 39.